Completed PHASE2 INTERVENTIONAL 2-arm NCT01752907

Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim (VINE)

Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim

Sponsor: Amgen

Conditions Breast Cancer

Interventions Bone Pain Education DVD General Education DVD

Updated 7 times since 2017 Last updated: Nov 4, 2022 Started: Jan 17, 2013 Primary completion: Dec 15, 2014 Completion: Dec 15, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Amgen and has accumulated 7 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Albuquerque, United States , Asheboro, United States , Bend, United States , Boston, United States , Bristol, United States , Burien, United States , Canton, United States , Cedar Rapids, United States , Charlotte, United States and 41 more locations